Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.

Nanni P, Landuzzi L, Manara MC, Righi A, Nicoletti G, Cristalli C, Pasello M, Parra A, Carrabotta M, Ferracin M, Palladini A, Ianzano ML, Giusti V, Ruzzi F, Magnani M, Donati DM, Picci P, Lollini PL, Scotlandi K.

Sci Rep. 2019 Aug 21;9(1):12174. doi: 10.1038/s41598-019-48634-y.

2.

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R.

De Giovanni C, Landuzzi L, Palladini A, Ianzano ML, Nicoletti G, Ruzzi F, Amici A, Croci S, Nanni P, Lollini PL.

Cancers (Basel). 2019 Apr 11;11(4). pii: E517. doi: 10.3390/cancers11040517.

3.

Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis.

De Giovanni C, Nanni P, Landuzzi L, Ianzano ML, Nicoletti G, Croci S, Palladini A, Lollini PL.

BMC Cancer. 2019 Feb 7;19(1):126. doi: 10.1186/s12885-019-5339-4.

4.

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis.

Nanni P, De Giovanni C, Burocchi A, Nicoletti G, Landuzzi L, Palladini A, Ianzano ML, Arioli I, Colombo MP, Lollini PL.

Oncoimmunology. 2018 Jun 11;7(8):e1465164. doi: 10.1080/2162402X.2018.1465164. eCollection 2018.

5.

A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy.

Manara MC, Valente S, Cristalli C, Nicoletti G, Landuzzi L, Zwergel C, Mazzone R, Stazi G, Arimondo PB, Pasello M, Guerzoni C, Picci P, Nanni P, Lollini PL, Mai A, Scotlandi K.

Mol Cancer Ther. 2018 Sep;17(9):1881-1892. doi: 10.1158/1535-7163.MCT-17-0818. Epub 2018 Jun 29.

6.

Cancer immunoprevention: from mice to early clinical trials.

Palladini A, Landuzzi L, Lollini PL, Nanni P.

BMC Immunol. 2018 Jun 15;19(1):16. doi: 10.1186/s12865-018-0253-0. Review.

7.

Virus-like particle display of HER2 induces potent anti-cancer responses.

Palladini A, Thrane S, Janitzek CM, Pihl J, Clemmensen SB, de Jongh WA, Clausen TM, Nicoletti G, Landuzzi L, Penichet ML, Balboni T, Ianzano ML, Giusti V, Theander TG, Nielsen MA, Salanti A, Lollini PL, Nanni P, Sander AF.

Oncoimmunology. 2018 Jan 5;7(3):e1408749. doi: 10.1080/2162402X.2017.1408749. eCollection 2018.

8.

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.

Palladini A, Nicoletti G, Lamolinara A, Dall'Ora M, Balboni T, Ianzano ML, Laranga R, Landuzzi L, Giusti V, Ceccarelli C, Santini D, Taffurelli M, Di Oto E, Asioli S, Amici A, Pupa SM, De Giovanni C, Tagliabue E, Iezzi M, Nanni P, Lollini PL.

Oncotarget. 2017 Apr 13;8(33):54444-54458. doi: 10.18632/oncotarget.17088. eCollection 2017 Aug 15.

9.

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.

Croci S, Nanni P, Palladini A, Nicoletti G, Grosso V, Benegiamo G, Landuzzi L, Lamolinara A, Ianzano ML, Ranieri D, Dall'Ora M, Iezzi M, De Giovanni C, Lollini PL.

Breast Cancer Res. 2015 May 22;17:70. doi: 10.1186/s13058-015-0588-x.

10.

Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas.

Landuzzi L, Ianzano ML, Nicoletti G, Palladini A, Grosso V, Ranieri D, Dall'Ora M, Raschi E, Laranga R, Gambarotti M, Picci P, De Giovanni C, Nanni P, Lollini PL.

Oncotarget. 2014 Dec 15;5(23):11924-38.

11.

Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers.

Riccardo F, Arigoni M, Buson G, Zago E, Iezzi M, Longo D, Carrara M, Fiore A, Nuzzo S, Bicciato S, Nanni P, Landuzzi L, Cavallo F, Calogero R, Quaglino E.

BMC Genomics. 2014;15 Suppl 3:S1. doi: 10.1186/1471-2164-15-S3-S1. Epub 2014 May 6.

12.

An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas.

Guerzoni C, Amatori S, Giorgi L, Manara MC, Landuzzi L, Lollini PL, Tassoni A, Balducci M, Manfrini M, Pratelli L, Serra M, Picci P, Magnani M, Fusi V, Fanelli M, Scotlandi K.

BMC Cancer. 2014 Feb 27;14:137. doi: 10.1186/1471-2407-14-137.

13.

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.

De Giovanni C, Nicoletti G, Quaglino E, Landuzzi L, Palladini A, Ianzano ML, Dall'Ora M, Grosso V, Ranieri D, Laranga R, Croci S, Amici A, Penichet ML, Iezzi M, Cavallo F, Nanni P, Lollini PL.

Breast Cancer Res. 2014 Jan 23;16(1):R10. doi: 10.1186/bcr3602.

14.

Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug.

Garofalo C, Capristo M, Manara MC, Mancarella C, Landuzzi L, Belfiore A, Lollini PL, Picci P, Scotlandi K.

PLoS One. 2013 Dec 31;8(12):e83832. doi: 10.1371/journal.pone.0083832. eCollection 2013.

15.

Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.

Ianzano ML, Croci S, Nicoletti G, Palladini A, Landuzzi L, Grosso V, Ranieri D, Dall'Ora M, Santeramo I, Urbini M, De Giovanni C, Lollini PL, Nanni P.

Oncotarget. 2014 Jan 15;5(1):108-19.

16.

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma.

Tavanti E, Sero V, Vella S, Fanelli M, Michelacci F, Landuzzi L, Magagnoli G, Versteeg R, Picci P, Hattinger CM, Serra M.

Br J Cancer. 2013 Nov 12;109(10):2607-18. doi: 10.1038/bjc.2013.643. Epub 2013 Oct 15.

17.

Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.

Nanni P, Gatta V, Menotti L, De Giovanni C, Ianzano M, Palladini A, Grosso V, Dall'ora M, Croci S, Nicoletti G, Landuzzi L, Iezzi M, Campadelli-Fiume G, Lollini PL.

PLoS Pathog. 2013 Jan;9(1):e1003155. doi: 10.1371/journal.ppat.1003155. Epub 2013 Jan 31.

18.

Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.

De Giovanni C, Nicoletti G, Landuzzi L, Romani F, Croci S, Palladini A, Murgo A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Iezzi M, Stramucci L, Barbieri E, Lemoli RM, Nanni P, Lollini PL.

Br J Cancer. 2012 Oct 9;107(8):1302-9. doi: 10.1038/bjc.2012.394. Epub 2012 Aug 28.

19.

Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor.

Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, Grosso V, Stivani V, Antognoli A, Lamolinara A, Landuzzi L, di Tomaso E, Iezzi M, De Giovanni C, Lollini PL.

PLoS One. 2012;7(6):e39626. doi: 10.1371/journal.pone.0039626. Epub 2012 Jun 21.

20.

Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy.

Pasello M, Manara MC, Michelacci F, Fanelli M, Hattinger CM, Nicoletti G, Landuzzi L, Lollini PL, Caccuri A, Picci P, Scotlandi K, Serra M.

Anal Cell Pathol (Amst). 2011;34(3):131-45. doi: 10.3233/ACP-2011-012.

21.

HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines.

Landuzzi L, Antognoli A, Nicoletti G, Croci S, Palladini A, Ianzano ML, Murgo A, Stivani V, Grosso V, Nanni P, De Giovanni C, Lollini PL.

Vaccine. 2011 Jun 24;29(29-30):4690-7. doi: 10.1016/j.vaccine.2011.04.096. Epub 2011 May 11.

PMID:
21569812
22.

Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.

Pantaleo MA, Nicoletti G, Nanni C, Gnocchi C, Landuzzi L, Quarta C, Boschi S, Nannini M, Di Battista M, Castellucci P, Fanti S, Lollini PL, Bellan E, Castelli M, Rubello D, Biasco G.

J Exp Clin Cancer Res. 2010 Dec 30;29:173. doi: 10.1186/1756-9966-29-173.

23.

Vaccines and other immunological approaches for cancer immunoprevention.

Lollini PL, Nicoletti G, Landuzzi L, Cavallo F, Forni G, De Giovanni C, Nanni P.

Curr Drug Targets. 2011 Dec;12(13):1957-73. Review.

PMID:
21158706
24.

TRAF6 regulates proliferation and differentiation of skeletal myoblasts.

Mueck T, Berger F, Buechsler I, Valchanova RS, Landuzzi L, Lollini PL, Klingel K, Munz B.

Differentiation. 2011 Feb;81(2):99-106. doi: 10.1016/j.diff.2010.11.002. Epub 2010 Dec 4.

PMID:
21131124
25.

Immunoprevention and immunotherapy of mammary carcinoma.

Lollini PL, Nicoletti G, Landuzzi L, De Giovanni C, Nanni P.

Breast J. 2010 Sep-Oct;16 Suppl 1:S39-41. doi: 10.1111/j.1524-4741.2010.01002.x.

PMID:
21050308
26.

Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system.

Croci S, Recktenwald CV, Lichtenfels R, Nicoletti G, Dressler SP, De Giovanni C, Astolfi A, Palladini A, Shin-ya K, Landuzzi L, Nanni P, Lollini PL, Seliger B.

Proteomics. 2010 Nov;10(21):3835-53. doi: 10.1002/pmic.200900643.

PMID:
20957756
27.

In silico modeling and in vivo efficacy of cancer-preventive vaccinations.

Palladini A, Nicoletti G, Pappalardo F, Murgo A, Grosso V, Stivani V, Ianzano ML, Antognoli A, Croci S, Landuzzi L, De Giovanni C, Nanni P, Motta S, Lollini PL.

Cancer Res. 2010 Oct 15;70(20):7755-63. doi: 10.1158/0008-5472.CAN-10-0701. Epub 2010 Oct 5.

28.

Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.

Pantaleo MA, Mishani E, Nanni C, Landuzzi L, Boschi S, Nicoletti G, Dissoki S, Paterini P, Piccaluga PP, Lodi F, Lollini PL, Fanti S, Biasco G.

Mol Imaging Biol. 2010 Dec;12(6):616-25. doi: 10.1007/s11307-010-0315-z.

29.

NVP-BEZ235 as a new therapeutic option for sarcomas.

Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, García-Echeverría C, Mercuri M, Picci P, Scotlandi K.

Clin Cancer Res. 2010 Jan 15;16(2):530-40. doi: 10.1158/1078-0432.CCR-09-0816. Epub 2010 Jan 12.

30.

High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.

Nanni P, Nicoletti G, Landuzzi L, Croci S, Murgo A, Palladini A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Maira SM, García-Echeverría C, Scotlandi K, De Giovanni C, Lollini PL.

Eur J Cancer. 2010 Feb;46(3):659-68. doi: 10.1016/j.ejca.2009.11.018. Epub 2009 Dec 22.

PMID:
20031388
31.

Molecular and cellular biology of rhabdomyosarcoma.

De Giovanni C, Landuzzi L, Nicoletti G, Lollini PL, Nanni P.

Future Oncol. 2009 Nov;5(9):1449-75. doi: 10.2217/fon.09.97. Review.

PMID:
19903072
32.

The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis.

Paradiso A, Mangia A, Orlando C, Verderio P, Belfiglio M, Marchetti A, Bertario L, Chiappetta G, Gion M, Tonini GP, Podo F, Vocaturo A, Silvestrini R, Romani M, Belloni E, Cavallo D, Ulivi P, Tommasi S, Steffan A, Russo A, Alessio M, Calistri D, Zancan M, Parrela P, Broggini M, Giuseppe A, Buttitta F, Finocchiaro G, Mazzocco K, Veronesi G, Landuzzi L, Benevolo M, Mariani L, De Marco F, Venuti A, Giannelli G, Quaranta M, Trojano V.

Int J Biol Markers. 2009 Jul-Sep;24(3):119-29.

PMID:
19787622
33.

APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the Apc(Min) mouse model in vivo.

Sale S, Fong IL, de Giovanni C, Landuzzi L, Brown K, Steward WP, Gescher AJ.

Eur J Cancer. 2009 Nov;45(16):2731-5. doi: 10.1016/j.ejca.2009.07.004. Epub 2009 Aug 18.

PMID:
19695862
34.

Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP).

Zambelli D, Zuntini M, Nardi F, Manara MC, Serra M, Landuzzi L, Lollini PL, Ferrari S, Alberghini M, Llombart-Bosch A, Piccolo E, Iacobelli S, Picci P, Scotlandi K.

Int J Cancer. 2010 Jan 1;126(1):41-52. doi: 10.1002/ijc.24670.

35.

Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.

Menotti L, Nicoletti G, Gatta V, Croci S, Landuzzi L, De Giovanni C, Nanni P, Lollini PL, Campadelli-Fiume G.

Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9039-44. doi: 10.1073/pnas.0812268106. Epub 2009 May 20.

36.

Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy.

De Giovanni C, Nicoletti G, Landuzzi L, Croci S, Palladini A, Antognoli A, Murgo A, Ianzano ML, Grosso V, Stivani V, Iezzi M, Musiani P, Nanni P, Lollini PL.

Vaccine. 2009 Mar 23;27(14):2065-9. doi: 10.1016/j.vaccine.2009.01.113. Epub 2009 Jan 31.

PMID:
19428831
37.

Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4.

Nanni P, Nicoletti G, Palladini A, Astolfi A, Rinella P, Croci S, Landuzzi L, Monduzzi G, Stivani V, Antognoli A, Murgo A, Ianzano M, De Giovanni C, Lollini PL.

Mol Cancer Ther. 2009 Apr;8(4):754-61. doi: 10.1158/1535-7163.MCT-08-0678.

38.

Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model.

Pantaleo MA, Landuzzi L, Nicoletti G, Nanni C, Boschi S, Piazzi G, Santini D, Di Battista M, Castellucci P, Lodi F, Fanti S, Lollini PL, Biasco G.

Clin Exp Med. 2009 Sep;9(3):199-205. doi: 10.1007/s10238-009-0033-5. Epub 2009 Feb 19.

39.

A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome.

De Giovanni C, Nicoletti G, Palladini A, Croci S, Landuzzi L, Antognoli A, Murgo A, Astolfi A, Ferrini S, Fabbi M, Orengo AM, Amici A, Penichet ML, Aurisicchio L, Iezzi M, Musiani P, Nanni P, Lollini PL.

Hum Gene Ther. 2009 May;20(5):453-64. doi: 10.1089/hum.2008.172.

PMID:
19215191
40.

Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer.

Pantaleo MA, Nannini M, Maleddu A, Fanti S, Nanni C, Boschi S, Lodi F, Nicoletti G, Landuzzi L, Lollini PL, Biasco G.

Ann Oncol. 2009 Feb;20(2):213-26. doi: 10.1093/annonc/mdn625. Epub 2008 Oct 7. Review.

PMID:
18842614
41.

Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma.

Berardi AC, Marsilio S, Rofani C, Salvucci O, Altavista P, Perla FM, Diomedi-Camassei F, Uccini S, Kokai G, Landuzzi L, McDowell HP, Dominici C.

Anticancer Res. 2008 Mar-Apr;28(2A):763-9.

42.

Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis.

Croci S, Landuzzi L, Nicoletti G, Palladini A, Antognoli A, De Giovanni C, Nanni P, Lollini PL.

Pathol Oncol Res. 2007;13(4):336-9. Epub 2007 Dec 25.

43.

Antimetastatic activity of a preventive cancer vaccine.

Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Antognoli A, Landuzzi L, Fabbi M, Ferrini S, Musiani P, Iezzi M, De Giovanni C, Lollini PL.

Cancer Res. 2007 Nov 15;67(22):11037-44. Erratum in: Cancer Res. 2007 Dec 15;67(24):12034.

44.

RIP2 regulates growth and differentiation of normal myoblasts and of rhabdomyosarcoma cells.

Ehlers S, Mueck T, Adams S, Landuzzi L, Lollini PL, Munz B.

Eur J Cell Biol. 2008 Mar;87(3):163-72. Epub 2007 Oct 24.

PMID:
17961803
45.

Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells.

Croci S, Nicoletti G, Landuzzi L, Palladini A, Chiarini F, Nanni P, Lollini PL, De Giovanni C.

Oncol Rep. 2007 Aug;18(2):451-6.

PMID:
17611670
46.

Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.

Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, Nanni C, Hofmann F, García-Echeverría C, Picci P, Scotlandi K.

Clin Cancer Res. 2007 Feb 15;13(4):1322-30.

47.

Inhibition of prostate carcinogenesis by combined active immunoprophylaxis.

De Giovanni C, Croci S, Nicoletti G, Landuzzi L, Palladini A, Pannellini T, Borgia L, Iezzi M, Di Carlo E, Orengo AM, Kennedy RC, Lollini PL, Nanni P, Musiani P.

Int J Cancer. 2007 Jul 1;121(1):88-94.

48.

Endothelin-3 production by human rhabdomyosarcoma: a possible new marker with a paracrine role.

Palladini A, Astolfi A, Croci S, De Giovanni C, Nicoletti G, Rosolen A, Sartori F, Lollini PL, Landuzzi L, Nanni P.

Eur J Cancer. 2006 Mar;42(5):680-7. Epub 2006 Jan 24.

PMID:
16439111
49.

CD99 acts as an oncosuppressor in osteosarcoma.

Manara MC, Bernard G, Lollini PL, Nanni P, Zuntini M, Landuzzi L, Benini S, Lattanzi G, Sciandra M, Serra M, Colombo MP, Bernard A, Picci P, Scotlandi K.

Mol Biol Cell. 2006 Apr;17(4):1910-21. Epub 2006 Jan 18.

50.

Toward the definition of immunosuppressive regimens with antitumor activity.

Casadio F, Croci S, D'Errico Grigioni A, Corti B, Grigioni WF, Landuzzi L, Lollini PL.

Transplant Proc. 2005 Jun;37(5):2144-7.

PMID:
15964362

Supplemental Content

Loading ...
Support Center